首页> 美国卫生研究院文献>PLoS Clinical Trials >Biopsy-Controlled Liver Fibrosis Staging Using the Enhanced Liver Fibrosis (ELF) Score Compared to Transient Elastography
【2h】

Biopsy-Controlled Liver Fibrosis Staging Using the Enhanced Liver Fibrosis (ELF) Score Compared to Transient Elastography

机译:与瞬时弹性成像相比,使用增强型肝纤维化(ELF)评分进行活检控制的肝纤维化分期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Background and AimsChronic liver diseases are characterized by inflammatory and fibrotic liver injuries that often result in liver cirrhosis with its associated complications such as portal hypertension and hepatocellular carcinoma. Liver biopsy still represents the reference standard for fibrosis staging, although transient elastography is increasingly used for non-invasive monitoring of fibrosis progression. However, this method is not generally available and is associated with technical limitations emphasizing the need for serological biomarkers staging of liver fibrosis. The enhanced liver fibrosis (ELF) score was shown to accurately predict significant liver fibrosis in different liver diseases, although extracellular matrix components detected by this score may not only mirror the extent of liver fibrosis but also inflammatory processes.
机译:背景和目的慢性肝病的特征是炎症性和纤维化性肝损伤,通常会导致肝硬化及其相关并发症,例如门脉高压和肝细胞癌。肝活检仍代表了纤维化分期的参考标准,尽管瞬时弹性成像已越来越多地用于非侵入性监测纤维化进程。然而,该方法通常不可用,并且与强调肝纤维化的血清学生物标志物分期的技术限制有关。增强的肝纤维化(ELF)评分显示可准确预测不同肝脏疾病中的严重肝纤维化,尽管通过该评分检测到的细胞外基质成分不仅可以反映肝纤维化的程度,还可以反映炎症过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号